Kerecis Announces First European Center of Excellence for Medical Fish-Skin Technology
11.12.2024 07:00:00 CET | Business Wire | Press release
Munich Clinic Recognized for Leadership in Advancing Tissue Regeneration Solutions
Kerecis, the pioneer in the use of fish skin and fatty acids for tissue regeneration and protection, announces the designation of its first European Center of Excellence: the Chirurgische Praxisklinik am Friedensengel in Munich, Germany.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241211672067/en/
Dan Coaten (right) presents Dr. Sandra Moritz (center) with the Kerecis Center of Excellence certification. (Photo: Business Wire)
Kerecis Centers of Excellence are hubs for peer-to-peer mentoring, advanced training, and collaborative research into innovative applications of Kerecis fish-skin technology. These centers foster the sharing of best practices and provide expert guidance to enhance patient care using Kerecis products.
This marks a milestone for Kerecis, as the recognition extends its Center of Excellence program beyond the United States for the first time. The designation honors hospitals and private practices that facilitate the sharing of best practices, provide expert guidance, and serve as hubs for training and research using Kerecis products.
The Chirurgische Praxisklinik am Friedensengel, an outpatient clinic for general surgery and traumatology, is led by Dr. Sandra Moritz, a general surgeon specializing in natural and biological treatment methods. Dr. Moritz has been an advocate of Kerecis fish-skin technology for over six years, using the fish-skin to treat severe wounds and tissue damage where the standard of care fails to provide adequate outcomes. As an early adopter of Kerecis technology, Dr. Moritz frequently shares her expertise at medical conferences and events worldwide.
The Chirurgische Praxisklinik am Friedensengel will join two existing Kerecis Centers of Excellence in the United States, contributing to a growing global network of leading institutions dedicated to advancing tissue regeneration solutions.
“This recognition of Chirurgische Praxisklinik am Friedensengel as our first European Center of Excellence underscores Kerecis’ growing presence and recognition in Germany,” said Fertram Sigurjonsson, Founder and CEO of Kerecis. “Dr. Moritz and her team exemplify the innovation, expertise, and dedication that drive advancements in tissue regeneration.”
“I cannot imagine running my practice without Kerecis fish-skin, I use it on a variety of conditions daily. I am extremely grateful for this treatment option for my patients,” said Dr. Moritz.
About Kerecis
Kerecis, founded by Fertram Sigurjonsson, develops fish skin and fatty acid products for cellular therapy, tissue regeneration, and protection. When grafted onto damaged human tissue or implanted, the patented material supports the body’s own processes to heal and regenerate. Because no disease-transfer risk exists between cold-water fish and humans, the Kerecis fish-skin is only gently processed and retains its similarity to human tissue. The gentle processing preserves the skin’s original three-dimensional structure, maintaining its inherent natural strength, complexity, and molecules (such as fatty acids). Clinical studies show that Kerecis products heal wounds faster than competitors. Kerecis is the only global manufacturer of medical devices containing intact fish-skin and is the fastest growing company in the U.S. biologics skin market. Products include SurgiBind®, GraftGuide®, MariGen®, and Shield™ for various medical applications. Committed to the UN Sustainable Development Goals, Kerecis uses sustainable Icelandic fish processed with renewable energy. Kerecis is a part of Coloplast, a leading supplier of intimate healthcare products. For more information, visit https://www.kerecis.com.
Trademarks and registered trademarks are the property of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241211672067/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Egon Zehnder and IMD Join Forces to Boost Board Performance and Leadership Growth12.3.2026 09:00:00 CET | Press release
Egon Zehnder, the world’s premier leadership advisory and executive search firm, and IMD, the leading business school in global executive education, today announced a strategic partnership to facilitate board directors’ personal growth and elevate board performance. The partnership combines IMD's academic rigor and deep connections to global boards with Egon Zehnder's unparalleled expertise in leadership and board effectiveness. Together, they will co-create tailored development experiences that blend research, real-world diagnostics, and practical guidance to support directors navigating today's complex business environment. IMD’s research clearly shows that good governance is a driver of both corporate success and national competitiveness. Egon Zehnder’s global work in supporting the personal development of board directors and chairs has shown that, in times of accelerating change, this has become a decisive factor for success. “This collaboration comes at a pivotal moment,” said Dav
COOLMAX CloakFX™ Fiber Makes Official Global Debut at Performance Days Munich12.3.2026 09:00:00 CET | Press release
The LYCRA Company’s latest innovation minimizes the visible appearance of sweat while delivering moisture management to activewear, ready-to-wear and workwear The LYCRA Company will officially launch COOLMAX CloakFX™ fiber globally at Performance Days Munich, Europe’s leading functional fabric fair, March 18–19. This innovation is designed to help garments appear drier by minimizing visible sweat marks while delivering moisture management and cooling comfort. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260317950119/en/ COOLMAX CloakFX™ fiber, the latest innovation from The LYCRA Company, helps garments appear drier by minimizing visible sweat marks and delivering moisture-wicking, cooling performance. Photo credit: The LYCRA Company COOLMAX CloakFX™ fiber is for brands, mills, and garment makers creating performance-driven activewear, workwear, and everyday apparel. The technology diffuses light at the fiber level using o
EcoOnline Launches Mega Trends Report as 2025 Momentum Reflects the Shift from Compliance to Connected Risk12.3.2026 09:00:00 CET | Press release
Eighteen months of EcoOnline primary research highlights seven shifts reshaping safety and sustainability, mirrored in the company’s 2025 customer adoption, product innovation, and growth. EcoOnline, a leading global provider of safety and sustainability software, today announced its inaugural EcoOnline Mega Trends Report, based on 18 months of primary research with business leaders and frontline workers. Seven mega trends reshaping the risk landscape The findings show a market-wide sense of urgency and shift towards connected risk data and vendor consolidation, with organisations increasingly treating compliance as the baseline while prioritising improved operations visibility, faster decision-making, and a need to future-proof their businesses with real-time insights and operational readiness. The report outlines seven macro trends, from the chemical safety maturity gap and the rise of lone work and contractor reliance to the central role of training and frontline engagement, and the
Redslim expands into Asia-Pacific to support global brands with data and AI infrastructure12.3.2026 07:00:00 CET | Press release
Redslim, a specialist in end-to-end data management solutions and an Astorg portfolio company, today announced its expansion into the Asia-Pacific region and the appointment of Kyriakos Zannikos as Regional Director, APAC. The move marks an important milestone in Redslim’s global growth strategy and brings the company closer to clients operating in one of the world’s fastest-growing and most data-driven consumer markets. As global consumer brands accelerate digital transformation and AI adoption, many organizations still struggle with fragmented data ecosystems spanning multiple agencies, markets and datasets. These challenges are particularly pronounced in Asia-Pacific, where diverse market structures and rapid growth create complex data environments. Redslim helps organizations transform fragmented market information into valuable data assets, empowering clients to make confident decisions and unlock the full value of their data. By building strong data foundations, Redslim supports
Meiji Seika Pharma Initiates Phase I Clinical Trial in Australia Evaluating ME3241, an Anti-PD-1 Agonist Antibody Discovered Through Collaborative Research With FBRI12.3.2026 07:00:00 CET | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Chuo-ku, Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) announced today that it has initiated a Phase I clinical trial of ME3241 (development code), an anti-PD-1 agonist monoclonal antibody discovered through collaborative research with the Foundation for Biomedical Research and Innovation at Kobe (Headquarters: Kobe, Japan; President: Shuh Narumiya; hereinafter “FBRI”). The Phase I clinical trial is designed as a randomized, placebo-controlled, double-blind study, with the objective of evaluating the safety and tolerability of ME3241 following single and multiple dosing, as well as its pharmacokinetics and pharmacodynamics (ClinicalTrials.gov: NCT07422207). ME3241 was discovered through a collaborative research program led by Program Director Tasuku Honjo, a professor emeritus at Kyoto University. PD-1 is a molecule expressed on activated T cells and other lymphocytes that suppresses immune responses. Through this re
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom